Press Releases

The Ministry of Health proceeds with the administration of a booster dose of the vaccine at home to bedridden patients, following the same procedure applied during the initial phase of the National Vaccination Plan against COVID-19.

In particular, individuals who have been vaccinated at home during the initial stage of the vaccination plan and are still bedridden, will have the possibility, if they so wish, to receive the 3rd dose in their place of residence. Beneficiaries should complete the Consent Form and present it together with the identification form and the initial vaccination card on the day of their vaccination.

In addition, individuals who during the initial phase of the Vaccination Programme were not vaccinated at home, but are currently bedridden due to a health problem, can apply for home vaccination, duly completing Form B. This form should be sent both signed by the beneficiary or his representative and by the Personal Doctor to fax number 22605491.

Vaccination will be carried out with an mRNA vaccine. For home administration of the booster dose six months must have elapsed since vaccination with the 2nd dose and the bedridden patients must fall within the following population categories:

1. Persons aged 60 and over
2. Persons falling within the following groups, regardless of age:

• In active therapy for solid tumors and haematological malignancies
• With a history of transplantation of solid organs, receiving immunosuppressive therapy
• With a history of transplantation of stem hematopoietic organs receiving immunosuppressive therapy
• With hereditary immunodeficiency
• With HIV Infection/AIDS
• In immunosuppressive therapy including biological agents. As regards cortisone intake, it refers individuals who received or receive a total dose of >10 mg prednisone/day (=8 mg of methylprednisolone) for 1 month in the last six months.
• With severe chronic respiratory disease
• With severe chronic cardiac and vascular disease
• With severe chronic kidney disease
• With severe chronic liver disease
• With severe chronic neurological disease
• With Diabetes Melitus and other endocrine diseases
• With haemoglobinopathies.

(ΕΚ)